Increased AHP Amplitude and decreased AP firing in the presence of kainic acid is dependent on the GluR5 subunit. by Barbara Gisabella (330774)

“…UBP296 failed to induce any electrophysiological changes in control rats (<b>A</b>–<b>E</b>). <b>E</b>, This panel shows representative traces recorded before and after application of UBP296 in PICRO versus SAL rats. …”

Optogenetic Recruitment of Dorsal Raphe Serotonergic Neurons Acutely Decreases Mechanosensory Responsivity in Behaving Mice by Guillaume P. Dugué (620333)

“…<i>In vivo</i>, the photoactivation of dorsal raphe serotonergic neurons gave rise to a prominent light-evoked field response that displayed some sensitivity to a 5-HT1A agonist, consistent with autoreceptor inhibition of raphe neurons. …”

NSE-apoE4, but not GFAP-apoE4, mice have decreased spine density in the auditory cortex at 19–21 months of age. by Sachi Jain (108277)

FGF10 dose dependency of the cellular response in E13.5 (black) and E14.5 (blue) epithelium. by Hisako Takigawa-Imamura (3175320)

Increased body weight and decreased expansion of pro-inflammatory CD4+ T-cells from blood in Tg-HD5 rats. by Osiris Marroquin Belaunzaran (224031)

The m⁶A peak of 3’UTR of TLR4 mRNA decreases significantly in METTL14-knockdown PK-15 cells. by Jing Chen (4762)

FASN inhibitors result in decreased ΔΨm and increased superoxide production in melan-a cells. by Franco A. Rossato (588513)

FASN inhibitors result in decreased ΔΨm and increased superoxide production in melan-a cells. by Franco A. Rossato (588513)

Resveratrol decreases CYP17A1 and CYP21A2 protein expression. by Nesa Marti (3851059)

“…<p>A. Gene expression profiling by qRT-PCR was performed for CYP17, CYP21 and their cofactor POR in H295R cells grown under normal conditions (GM), starvation conditions (SM), metformin (Met) (1mM) treatment and under resveratrol (RSV) (5<u>μM)</u> treatment. …”

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)